EGFR-mutated advanced lung cancer. Data from a single institution, the Hospital of Leon, in Spain

Introduction 10–16% of non-small cell lung cancer (NSCLC) cases have the epidermal growth factor receptor (EGFR) amplified and/or mutated. Studies show that EGFR tyrosine kinase inhibitors (TKIs) significantly prolong progression-free survival (PFS) in patients with advanced NSCLC compared to those...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of oncology pharmacy practice 2023-06, Vol.29 (4), p.854-860
Hauptverfasser:	Delgado Sillero, Irene, Lopetegui Lia, Nerea, Sánchez Cousido, Luis Felipe, Rojas Piedra, Mariam, Távara Silva, Blanca, Garrido Onecha, Maria Luisa, Medina Valdivieso, Soledad, Alonso Horcajo, Nieves, Díez Tascón, Cristina, López González, Ana, Castañón López, Carmen, Pedraza Lorenzo, Manuela, García Palomo, Andrés, Martín, Vicente, Diz Tain, Pilar
Format:	Artikel
Sprache:	eng
Schlagworte:	Asthenia Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - genetics Chemotherapy Clinical trials Conjunctivitis Diarrhea Epidermal growth factor receptors ErbB Receptors - genetics Gefitinib Hospitals Humans Lung cancer Lung Neoplasms - drug therapy Lung Neoplasms - genetics Metastases Mutation Non-small cell lung carcinoma Patients Protein Kinase Inhibitors - therapeutic use Protein-tyrosine kinase Quinazolines - adverse effects Regression analysis Retrospective Studies Risk factors Small cell lung carcinoma Spain Survival analysis Targeted cancer therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!